130 related articles for article (PubMed ID: 29371409)
1. The National Oncology PET Registry (NOPR): A monumental effort by a few leaders.
Czernin J
J Nucl Med; 2018 Jan; ():. PubMed ID: 29371409
[No Abstract] [Full Text] [Related]
2. The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders.
Czernin J
J Nucl Med; 2018 Mar; 59(3):379. PubMed ID: 29497001
[No Abstract] [Full Text] [Related]
3. The National Oncologic PET Registry (NOPR): design and analysis plan.
Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
[TBL] [Abstract][Full Text] [Related]
4. Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.
Hillner BE; Siegel BA; Shields AF; Duan F; Gareen IF; Hanna L; Coleman RE
Mol Imaging Biol; 2011 Feb; 13(1):161-5. PubMed ID: 21080232
[TBL] [Abstract][Full Text] [Related]
5. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.
Hillner BE; Tosteson AN; Tosteson TD; Wang Q; Song Y; Hanna LG; Siegel BA
J Nucl Med; 2013 Dec; 54(12):2024-31. PubMed ID: 24221994
[TBL] [Abstract][Full Text] [Related]
6. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
Lindsay MJ; Siegel BA; Tunis SR; Hillner BE; Shields AF; Carey BP; Coleman RE
AJR Am J Roentgenol; 2007 Apr; 188(4):1109-13. PubMed ID: 17377055
[TBL] [Abstract][Full Text] [Related]
7. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
[TBL] [Abstract][Full Text] [Related]
8. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
[TBL] [Abstract][Full Text] [Related]
9. Hospice Admission and Survival After
Gareen IF; Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Siegel BA
J Nucl Med; 2018 Mar; 59(3):427-433. PubMed ID: 29284672
[TBL] [Abstract][Full Text] [Related]
10. The National Oncologic PET Registry: lessons learned for coverage with evidence development.
Tunis S; Whicher D
J Am Coll Radiol; 2009 May; 6(5):360-5. PubMed ID: 19394577
[TBL] [Abstract][Full Text] [Related]
11. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
12. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.
Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA
Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033
[TBL] [Abstract][Full Text] [Related]
13. The nociceptin receptor (NOPR) and its interaction with clinically important agonist molecules: a membrane molecular dynamics simulation study.
Kothandan G; Gadhe CG; Balupuri A; Ganapathy J; Cho SJ
Mol Biosyst; 2014 Dec; 10(12):3188-98. PubMed ID: 25259728
[TBL] [Abstract][Full Text] [Related]
14. Serine 363 is required for nociceptin/orphanin FQ opioid receptor (NOPR) desensitization, internalization, and arrestin signaling.
Zhang NR; Planer W; Siuda ER; Zhao HC; Stickler L; Chang SD; Baird MA; Cao YQ; Bruchas MR
J Biol Chem; 2012 Dec; 287(50):42019-30. PubMed ID: 23086955
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
[TBL] [Abstract][Full Text] [Related]
16. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hunt E; Coleman RE
J Nucl Med; 2008 Dec; 49(12):1928-35. PubMed ID: 18997054
[TBL] [Abstract][Full Text] [Related]
17. Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol.
Bojnik E; Farkas J; Magyar A; Tömböly C; Güçlü U; Gündüz O; Borsodi A; Corbani M; Benyhe S
Neurochem Int; 2009 Dec; 55(7):458-66. PubMed ID: 19414055
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases.
Li Y; Schiepers C; Lake R; Dadparvar S; Berenji GR
Bone; 2012 Jan; 50(1):128-39. PubMed ID: 22001678
[TBL] [Abstract][Full Text] [Related]
19. Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships.
Mustazza C; Pieretti S; Marzoli F
Curr Med Chem; 2018; 25(20):2353-2384. PubMed ID: 29332567
[TBL] [Abstract][Full Text] [Related]
20. Nociceptin/orphanin FQ receptor modulates painful and fatigue symptoms in a mouse model of fibromyalgia.
Dagnino APA; da Silva RBM; Chagastelles PC; Pereira TCB; Venturin GT; Greggio S; Costa da Costa J; Bogo MR; Campos MM
Pain; 2019 Jun; 160(6):1383-1401. PubMed ID: 30720581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
